Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Deletion of the monkeypox virus inhibitor of complement enzymes locus impacts the adaptive immune response to monkeypox virus in a nonhuman primate model of infection.

Estep RD, Messaoudi I, O'Connor MA, Li H, Sprague J, Barron A, Engelmann F, Yen B, Powers MF, Jones JM, Robinson BA, Orzechowska BU, Manoharan M, Legasse A, Planer S, Wilk J, Axthelm MK, Wong SW.

J Virol. 2011 Sep;85(18):9527-42. doi: 10.1128/JVI.00199-11. Epub 2011 Jul 13.

2.

A-type inclusion bodies: a factor influencing cowpox virus lesion pathogenesis.

Leite JA, da Fonseca FG, de Souza Trindade G, Abrahão JS, Arantes RM, de Almeida-Leite CM, dos Santos JR, Guedes MI, Ribeiro BM, Bonjardim CA, Ferreira PC, Kroon EG.

Arch Virol. 2011 Apr;156(4):617-28. doi: 10.1007/s00705-010-0900-0. Epub 2011 Jan 7.

PMID:
21212997
3.

The Vaccinia virus complement control protein modulates adaptive immune responses during infection.

Girgis NM, Dehaven BC, Xiao Y, Alexander E, Viner KM, Isaacs SN.

J Virol. 2011 Mar;85(6):2547-56. doi: 10.1128/JVI.01474-10. Epub 2010 Dec 29.

4.

Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.

Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe JJ.

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16262-7. doi: 10.1073/pnas.1005769107. Epub 2010 Aug 30.

5.

Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.

DeHaven BC, Girgis NM, Xiao Y, Hudson PN, Olson VA, Damon IK, Isaacs SN.

J Virol. 2010 Nov;84(21):11245-54. doi: 10.1128/JVI.00372-10. Epub 2010 Aug 18.

6.

Dosage comparison of Congo Basin and West African strains of monkeypox virus using a prairie dog animal model of systemic orthopoxvirus disease.

Hutson CL, Carroll DS, Self J, Weiss S, Hughes CM, Braden Z, Olson VA, Smith SK, Karem KL, Regnery RL, Damon IK.

Virology. 2010 Jun 20;402(1):72-82. doi: 10.1016/j.virol.2010.03.012. Epub 2010 Apr 5.

7.

Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP.

J Immunol. 2009 Sep 1;183(5):3150-9. doi: 10.4049/jimmunol.0901366. Epub 2009 Aug 10.

8.

A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus.

Hutson CL, Olson VA, Carroll DS, Abel JA, Hughes CM, Braden ZH, Weiss S, Self J, Osorio JE, Hudson PN, Dillon M, Karem KL, Damon IK, Regnery RL.

J Gen Virol. 2009 Feb;90(Pt 2):323-33. doi: 10.1099/vir.0.005108-0.

PMID:
19141441
9.

Surviving mousepox infection requires the complement system.

Moulton EA, Atkinson JP, Buller RM.

PLoS Pathog. 2008 Dec;4(12):e1000249. doi: 10.1371/journal.ppat.1000249. Epub 2008 Dec 26.

10.

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement.

Benhnia MR, McCausland MM, Moyron J, Laudenslager J, Granger S, Rickert S, Koriazova L, Kubo R, Kato S, Crotty S.

J Virol. 2009 Feb;83(3):1201-15. doi: 10.1128/JVI.01797-08. Epub 2008 Nov 19.

11.

Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment.

Liszewski MK, Bertram P, Leung MK, Hauhart R, Zhang L, Atkinson JP.

J Immunol. 2008 Sep 15;181(6):4199-207.

12.

The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination.

Xu RH, Cohen M, Tang Y, Lazear E, Whitbeck JC, Eisenberg RJ, Cohen GH, Sigal LJ.

J Exp Med. 2008 Apr 14;205(4):981-92. doi: 10.1084/jem.20071854. Epub 2008 Apr 7.

13.

Monkeypox zoonotic associations: insights from laboratory evaluation of animals associated with the multi-state US outbreak.

Hutson CL, Lee KN, Abel J, Carroll DS, Montgomery JM, Olson VA, Li Y, Davidson W, Hughes C, Dillon M, Spurlock P, Kazmierczak JJ, Austin C, Miser L, Sorhage FE, Howell J, Davis JP, Reynolds MG, Braden Z, Karem KL, Damon IK, Regnery RL.

Am J Trop Med Hyg. 2007 Apr;76(4):757-68.

PMID:
17426184
14.
15.

Detection of monkeypox virus with real-time PCR assays.

Li Y, Olson VA, Laue T, Laker MT, Damon IK.

J Clin Virol. 2006 Jul;36(3):194-203. Epub 2006 May 30.

PMID:
16731033
16.

Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Mehlhop E, Diamond MS.

J Exp Med. 2006 May 15;203(5):1371-81. Epub 2006 May 1.

17.

Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation.

Liszewski MK, Leung MK, Hauhart R, Buller RM, Bertram P, Wang X, Rosengard AM, Kotwal GJ, Atkinson JP.

J Immunol. 2006 Mar 15;176(6):3725-34.

18.

A tale of two clades: monkeypox viruses.

Likos AM, Sammons SA, Olson VA, Frace AM, Li Y, Olsen-Rasmussen M, Davidson W, Galloway R, Khristova ML, Reynolds MG, Zhao H, Carroll DS, Curns A, Formenty P, Esposito JJ, Regnery RL, Damon IK.

J Gen Virol. 2005 Oct;86(Pt 10):2661-72.

PMID:
16186219
19.

Identification of complement regulatory domains in vaccinia virus complement control protein.

Mullick J, Bernet J, Panse Y, Hallihosur S, Singh AK, Sahu A.

J Virol. 2005 Oct;79(19):12382-93.

20.

Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003.

Learned LA, Reynolds MG, Wassa DW, Li Y, Olson VA, Karem K, Stempora LL, Braden ZH, Kline R, Likos A, Libama F, Moudzeo H, Bolanda JD, Tarangonia P, Boumandoki P, Formenty P, Harvey JM, Damon IK.

Am J Trop Med Hyg. 2005 Aug;73(2):428-34.

PMID:
16103616

Supplemental Content

Support Center